| abstract |
The present invention belongs to the field of antibody engineering and provides fully humanized anti-PD-1 monoclonal antibodies, methods of obtaining the same, and uses thereof. The anti-PD-1 monoclonal antibody was selected from the fully synthesized antibody library, and the library was constructed by mutating the light chain CDRI-3 region and the heavy chain CDRI-3 region of the sequentially obtained antibodies through affinity maturation techniques, -1 < / RTI > monoclonal antibody. The antibody can be used for the treatment of tumors, inflammation, autoimmune diseases. |